v3.3.1.900
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Cash flows from operating activities    
Net loss $ (2,072,548) $ (1,271,934)
Adjustments to reconcile net loss to net cash used in operations:    
Depreciation 699 11,291
Amortization 88,142 85,039
Impairment of intangible assets 277,061  
Bad debt expense (benefit) (4,672) 4,492
Write down of inventory 369,586  
Unrealized (gain) loss on fair value of embedded derivatives (41,265) (31,924)
Accretion of interest on convertible note   129,414
Accretion of interest on debt discount 258,379  
Non-cash stock-based compensation expense 147,048 161,232
Non-cash settlement of prior debt owed (732,561) (769,148)
Accrued interest payable 20,075 66,498
Changes in assets and liabilities:    
Accounts receivable 54,440 422,733
Other receivables   21,096
Inventory 174,559 161,766
Prepaid expenses and other current assets 200,005 149,234
Other assets 135,773 14,132
Accounts payable 91,266 111,418
Accrued liabilities and accrued warranty (65,491) (44,935)
Deferred revenue (15,450) 20,000
Net cash used in operating activities (1,114,954) (759,596)
Cash flows from investing activities    
Acquisition of patents (42,373)  
Net cash used in investing activities (42,373)  
Cash flows from financing activities    
Borrowing on convertible notes payable   600,000
Repayment of notes payable (109,164) (130,480)
Proceeds from issuance of common stock 1,247,440 625,000
Repayments on capital lease obligations   (299)
Payment of placement agent and registration fees and other direct costs   (36,618)
Employee taxes paid for vesting of restricted stock   (8,692)
Net cash provided by financing activities 1,138,276 1,048,911
Net increase (decrease) in cash (19,051) 289,315
Cash    
Beginning of period 61,542 [1] 150,081
End of period 42,491 439,396
Supplemental cash flows disclosures:    
Cash paid during the period for interest 2,991 51,667
Supplemental disclosure of non-cash financing activity:    
Embedded derivative on convertible note issued 176,771 122,630
Embedded derivative converted to equity 88,333 102,731
Beneficial conversion feature on note refinance 500,000  
Grant of warrants on issue of convertible note   170,767
Refinance of line of credit to convertible note payable 500,000  
Preferred stock dividend, paid in common stock   18,927
Note issued in exchange for accounts payable   160,000
Conversion of preferred stock to common stock   1,168,787
Conversion of convertible note to common stock 670,531 392,612
Purchase Agreement Fees [Member]    
Supplemental disclosure of non-cash financing activity:    
Common stock issued 12,107  
To Settle Claim [Member]    
Supplemental disclosure of non-cash financing activity:    
Common stock issued   250,000
Notes Payable, Other Payables [Member]    
Supplemental disclosure of non-cash financing activity:    
Note issued in exchange for accounts payable $ 225,000  
Convertible Note Payable [Member] | Financial Advisory Services Fees [Member]    
Supplemental disclosure of non-cash financing activity:    
Note issued in exchange for accounts payable   $ 160,000
[1] The condensed consolidated balance sheet as of December 31, 2014 has been derived from the audited consolidated financial statements as of that date.